Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/ATP5F1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ATP5F1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ATP5F1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ATP5F1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/ATP5F1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ATP5F1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ATP5F1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ATP5F1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ATP5F1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ATP5F1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000920524 | Cervix | N_HPV | purine ribonucleoside triphosphate metabolic process | 10/534 | 82/18723 | 1.11e-04 | 2.18e-03 | 10 |
GO:000920624 | Cervix | N_HPV | purine ribonucleoside triphosphate biosynthetic process | 9/534 | 68/18723 | 1.29e-04 | 2.46e-03 | 9 |
GO:000914524 | Cervix | N_HPV | purine nucleoside triphosphate biosynthetic process | 9/534 | 69/18723 | 1.44e-04 | 2.66e-03 | 9 |
GO:004277624 | Cervix | N_HPV | mitochondrial ATP synthesis coupled proton transport | 5/534 | 19/18723 | 1.55e-04 | 2.77e-03 | 5 |
GO:199054223 | Cervix | N_HPV | mitochondrial transmembrane transport | 11/534 | 102/18723 | 1.57e-04 | 2.79e-03 | 11 |
GO:001969315 | Cervix | N_HPV | ribose phosphate metabolic process | 25/534 | 396/18723 | 1.91e-04 | 3.25e-03 | 25 |
GO:000914424 | Cervix | N_HPV | purine nucleoside triphosphate metabolic process | 10/534 | 88/18723 | 2.01e-04 | 3.37e-03 | 10 |
GO:000919924 | Cervix | N_HPV | ribonucleoside triphosphate metabolic process | 10/534 | 89/18723 | 2.21e-04 | 3.63e-03 | 10 |
GO:000920124 | Cervix | N_HPV | ribonucleoside triphosphate biosynthetic process | 9/534 | 74/18723 | 2.48e-04 | 3.97e-03 | 9 |
GO:000925915 | Cervix | N_HPV | ribonucleotide metabolic process | 24/534 | 385/18723 | 3.08e-04 | 4.70e-03 | 24 |
GO:001059421 | Cervix | N_HPV | regulation of endothelial cell migration | 17/534 | 232/18723 | 3.76e-04 | 5.43e-03 | 17 |
GO:001059521 | Cervix | N_HPV | positive regulation of endothelial cell migration | 12/534 | 133/18723 | 4.30e-04 | 5.99e-03 | 12 |
GO:000914224 | Cervix | N_HPV | nucleoside triphosphate biosynthetic process | 9/534 | 85/18723 | 7.02e-04 | 8.93e-03 | 9 |
GO:000911714 | Cervix | N_HPV | nucleotide metabolic process | 27/534 | 489/18723 | 8.79e-04 | 1.07e-02 | 27 |
GO:000915015 | Cervix | N_HPV | purine ribonucleotide metabolic process | 22/534 | 368/18723 | 9.40e-04 | 1.12e-02 | 22 |
GO:000675310 | Cervix | N_HPV | nucleoside phosphate metabolic process | 27/534 | 497/18723 | 1.12e-03 | 1.28e-02 | 27 |
GO:004354222 | Cervix | N_HPV | endothelial cell migration | 18/534 | 279/18723 | 1.14e-03 | 1.31e-02 | 18 |
GO:000914124 | Cervix | N_HPV | nucleoside triphosphate metabolic process | 10/534 | 112/18723 | 1.37e-03 | 1.49e-02 | 10 |
GO:00435361 | Cervix | N_HPV | positive regulation of blood vessel endothelial cell migration | 8/534 | 76/18723 | 1.43e-03 | 1.53e-02 | 8 |
GO:007252115 | Cervix | N_HPV | purine-containing compound metabolic process | 23/534 | 416/18723 | 2.03e-03 | 1.98e-02 | 23 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATP5F1 | SNV | Missense_Mutation | | c.155N>T | p.Gly52Val | p.G52V | P24539 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATP5F1 | SNV | Missense_Mutation | | c.482N>G | p.Gln161Arg | p.Q161R | P24539 | protein_coding | deleterious(0) | benign(0.184) | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
ATP5F1 | insertion | Frame_Shift_Ins | novel | c.116_117insCCTGATGACAAAGAACAGTACCTGTGTGGGGAGA | p.His40LeufsTer21 | p.H40Lfs*21 | P24539 | protein_coding | | | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
ATP5F1 | SNV | Missense_Mutation | novel | c.109G>T | p.Gly37Trp | p.G37W | P24539 | protein_coding | deleterious(0.01) | possibly_damaging(0.604) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ATP5F1 | SNV | Missense_Mutation | | c.373N>A | p.Asp125Asn | p.D125N | P24539 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
ATP5F1 | SNV | Missense_Mutation | | c.618G>A | p.Met206Ile | p.M206I | P24539 | protein_coding | tolerated(0.41) | benign(0.049) | TCGA-DS-A0VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ATP5F1 | SNV | Missense_Mutation | novel | c.385N>A | p.Glu129Lys | p.E129K | P24539 | protein_coding | deleterious(0.01) | benign(0.171) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
ATP5F1 | SNV | Missense_Mutation | rs770948319 | c.406G>A | p.Glu136Lys | p.E136K | P24539 | protein_coding | tolerated(0.52) | possibly_damaging(0.564) | TCGA-MU-A51Y-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ATP5F1 | SNV | Missense_Mutation | | c.582G>T | p.Lys194Asn | p.K194N | P24539 | protein_coding | deleterious(0.02) | probably_damaging(0.989) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ATP5F1 | SNV | Missense_Mutation | | c.189N>A | p.Phe63Leu | p.F63L | P24539 | protein_coding | tolerated(0.24) | benign(0.027) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |